Navigation Links
Two New Studies in the British Medical Journal Find That Bayer's Yaz and Yasmin Birth Control Pills Have an Increased Risk of Blood Clot
Date:4/22/2011

PHILADELPHIA, April 22, 2011 /PRNewswire-USNewswire/ -- The following release is being issued by law firms RodaNast, P.C.; Levin, Fishbein, Sedran & Berman and Feldman & Pinto:

According to two new studies published in the online edition of the British Medical Journal, Bayer's birth control pills Yaz and Yasmin, containing a new progestin drospirenone (DSRP), carry up to triple the risk of serious blood clots (known as venous thromboembolism) over traditional pills containing the progestin levonorgestrel (LNG).

Approximately 2,000 lawsuits have been filed in Pennsylvania before Philadelphia Court of Common Pleas Judge Sandra Mazer Moss, Coordinating Judge of the Complex Litigation Center.  Another 4,000 lawsuits are pending in federal court before the Judge David R. Herndon, who is overseeing the federal multidistrict litigation (MDL).  The lawsuits allege that Yaz and Yasmin have risks beyond those of traditional birth control pills and that Bayer over-promoted the drug without disclosing the higher risks. Bayer was warned by the Food and Drug Administration (FDA), in the fall of 2008, that Bayer's television advertisements were misleading and did not disclose the additional risks.

The findings of the new studies provide additional evidence that the older oral contraceptives "appear to be a safer choice with regard to venous thromboembolism than preparations containing drospirenone," says Dr. Susan Jick of Boston University's School of Medicine, who led the research team.

Judge Moss appointed three Pennsylvania lawyers as Liaison Counsel for the plaintiffs, including Michael M. Weinkowitz of Levin, Fishbein, Sedran & Berman, Philadelphia, Daniel N. Gallucci of RodaNast, P.C., Lancaster, and Rosemary Pinto of Feldman & Pinto, Philadelphia.  Dianne M. Nast, RodaNast, P.C. was appointed Pennsylvania Federal-State Liaison Counsel by the Honorable David Herndon.


'/>"/>
SOURCE RodaNast, P.C.; Levin, Fishbein, Sedran & Berman; Feldman & Pinto
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Cetero Research Seminars Provide Insights on Designing Accelerated Proof-of-Concept Studies
2. ConvaTec Supported Studies to be Presented at the 24th Annual Symposium on Advanced Wound Care (SAWC) and Wound Healing Society (WHS)
3. New Clinical Studies Reinforce the LAP-BAND® System is a Safe and Effective Weight-Loss Treatment for Obese Adults with Obesity-Related Comorbid Conditions
4. MAP Pharmaceuticals to Present Data From LEVADEX® Pharmacokinetics and Pharmacodynamics Safety Studies at the 63rd Annual Meeting of the American Academy of Neurology
5. Preclinical Studies in Pancreatic Cancer and Melanoma Demonstrated ADI-PEG 20 Works Synergistically With Inhibitors of Autophagy
6. Three Studies Presented at the 2011 SHEA Annual Scientific Meeting Show That the ICU Medical MicroCLAVE® Contributes to a Significant Decrease in Bacterial Transfer and Reduction in Bloodstream Infections
7. New Studies Show Clinical Advantages of Masimo Noninvasive Hemoglobin, PVI, and Perfusion Index in Critically-ill Patients
8. BioTox Sciences (BTS) Deploys eStudy™ Hosted Solution for Management of GLP & Non-GLP Preclinical Studies
9. Auxilium Pharmaceuticals, Inc. Completes Enrollment of XIAFLEX® Phase III Double-Blind Studies for Peyronies Disease
10. FDA Clears Palatin Technologies IND Filing to Commence Clinical Studies for Asthma
11. Women Get Short Shrift in Many Heart Device Studies, Despite Requirement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... 2016 - DCGI grants limited approval to ... disease - Stempeucel® becomes 5th off-the-shelf Stem cell product ... - Buerger,s Disease (also known as Thromboangiitis Obliterans) is ... and Globally - Prevalence of Buerger,s Disease is estimated ... per 10,000 persons in the European Community & USA ...
(Date:5/27/2016)... study highlights the necessity of health literacy within the technology advancement of diagnostic imaging. According ... , a majority of oncology patients undergo imaging screenings without understanding the nuanced risks ... ... ... Medical Diagnostic Imaging Ampronix ...
(Date:5/27/2016)... , May 27, 2016 ... innovative biopharma company focused on the highly lucrative ... a substantial pipeline of potential first-in-class or best-in-class ... are in development with strategic partners. HCM,s profitable ... fast-growing domestic market. We expect progress of the ...
Breaking Medicine Technology:
(Date:5/29/2016)... ... , ... "With 30 unique self-animating web themed intros and complete control over ... said Christina Austin - CEO of Pixel Film Studios. , ProIntro Web Volume ... Final Cut Pro X. Pixel Film Studios’ minimalistic titles allow users to add a ...
(Date:5/28/2016)... ... May 28, 2016 , ... "Color Grading media can be time ... preset onto their media," said Christina Austin - CEO of Pixel Film Studios. ... and easily add stylish color grades to their footage. A LUT is a Lookup ...
(Date:5/28/2016)... ... May 28, 2016 , ... After a year and a half of planning the Multiple ... The Multiple Pathways of Recovery Conference was held May 2 -4, 2016 at the ... United Kingdom came together to explore the many pathways individuals use to get into and ...
(Date:5/27/2016)... ... 2016 , ... More than a third of American adults are considered obese, ... has received increased attention in recent years, as an article published May ... loss, most people are familiar with the basic requirements of maintaining a healthy diet ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon ... to Women and Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel ... year, Geri Boone, Director of the MLTSS (Managed Long-Term Services and Supports) Program at ...
Breaking Medicine News(10 mins):